The formulary covers over 22 million US lives.
Several treatments for chronic obstructive pulmonary disease (COPD) and asthma from Boehringer Ingelheim were recently added to the Express Scripts (ESI) Commercial National Preferred Formulary.
The formulary covers over 22 million US lives. The changes took effect May 15, 2020.
The COPD treatments are:
In addition, tiotropium bromide (Spiriva Respimat) inhalation spray 1.25 mcg was added for asthma.
“This important decision will provide people living with asthma and COPD additional options to consider when making treatment decisions with their healthcare providers,” said Chris Marsh, senior vice president, market access at Boehringer Ingelheim, said in a statement. “Not only does this decision reinforce the value and impact of our respiratory portfolio, but it serves as another example of our commitment to ensure our medicines are available to our patients who need them.”
According to the CDC, COPD is the third-leading cause of death in the United States. Almost 15.7 million Americans reported that they have been diagnosed with COPD, but the CDC has said that actual numbers may be higher, because more than 50% of adults with low pulmonary function were not aware that they had COPD.
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More
Study: Decreased BMI Increases Severe Exacerbation, All-Cause Mortality Risk in Patients With COPD
April 10th 2024Decreased body mass index (BMI) in patients with chronic obstructive pulmonary disease (COPD) was linked to a higher risk of severe exacerbations and all-cause mortality, emphasizing the importance of monitoring BMI for managing COPD and predicting outcomes.
Read More
Study: 1 in 6 US Patients With COPD Suffers From Cost-Related Medication Nonadherence
April 3rd 2024Medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) is associated with increasing COPD symptoms, hospitalizations, morbidity, mortality, and health care expenditures.
Read More